
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 19, 2023, titled "Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 19, 2023, titled "Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences